Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series
Current Oncology · 2026
DOI: 10.3390/curroncol33080456 ↗Kurz gefasst
Fallbericht in der Zeitschrift Current Oncology, 2026. Verfasst von Giuseppe Di Lorenzo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Immunoconjugates, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Next-generation sequencing (NGS)-detected ERBB2 amplification occurs in a subset of urothelial carcinomas, but its role as a treatment-selection marker for trastuzumab deruxtecan (T-DXd) remains uncertain.
Methods
We retrospectively reviewed four patients with metastatic urothelial carcinoma treated with T-DXd in routine practice from 2024. Treatment selection was based on NGS-detected ERBB2 amplification because HER2 immunohistochemistry and in situ hybridization were unavailable.
Results
Four men aged 65–76 years received T-DXd: one in the second line and three in the fourth or fifth line. The best radiological responses, abstracted from contemporaneous radiology reports and oncology medical records, were complete response in one patient, partial response in one, and stable disease in two. Three patients had previously received enfortumab vedotin. Documented adverse events included fatigue, anemia, diarrhea, rash, and leukopenia. No interstitial lung disease or pneumonitis was documented in the available records.
Conclusions
These observations are descriptive and hypothesis-generating. They do not establish the efficacy or safety of T-DXd or validate ERBB2 amplification as a predictive biomarker, but they support prospective evaluation of genomic ERBB2 amplification when standard HER2 testing is unavailable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.
- School of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
- Associazione ORA ETS, 84134 Salerno, Italy.
- Oncology Unit, ASL NA3 Sud, 80059 Torre del Greco, Italy.
ORCID-Profile: Sara Di Lorenzo
Zitieren
APA
Di Lorenzo, G., Di Lorenzo, S., Verde, A., Strianese, O., Leo, L., & Buonerba, C. (2026). Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series. Current Oncology. https://doi.org/10.3390/curroncol33080456
Vancouver
Di Lorenzo G, Di Lorenzo S, Verde A, Strianese O, Leo L, Buonerba C. Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series. Current Oncology. 2026. doi:10.3390/curroncol33080456
BibTeX
@article{DiLorenzo2026,
author = {Di Lorenzo, Giuseppe and Di Lorenzo, Sara and Verde, Antonio and Strianese, Oriana and Leo, Luigi and Buonerba, Carlo},
title = {Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33080456}
}
EUVIMED